Nexvet Biopharma plc (Nasdaq: NVET) to Ring The Nasdaq Stock Market Closing Bell
November 23 2015 - 6:00AM
What: Nexvet Biopharma plc
(Nasdaq:NVET), a global, clinical-stage, veterinary biologics
developer, will visit the Nasdaq MarketSite in Times Square to
celebrate the successful completion of a pivotal study for NV-01,
its biologic therapy in development for the control of pain
associated with osteoarthritis in dogs.
In honor of the occasion, the co-founders of Nexvet, Dr.
Mark Heffernan, Chief Executive Officer and Dr. David Gearing,
Chief Scientific Officer, will ring the Closing
Bell.
Where: Nasdaq MarketSite – 4 Times Square
– 43rd & Broadway – Broadcast Studio
When: Monday, November 23, 2015 – 3:45
p.m. to 4:00 p.m. ET
Nexvet Biopharma plc Media Contact: David
Salisbury Berry & Company Public Relations (212)
253-8881 dsalisbury@berrypr.com
Nasdaq MarketSite: Will Briganti (646)
441-5012 William.Briganti@nasdaq.com
Feed Information: Fiber Line (Encompass
Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC
3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
Social Media: For multimedia features such
as exclusive content, photo postings, status updates and video of
bell ceremonies please visit our Facebook page
at: http://www.facebook.com/NASDAQ.
For photos from ceremonies and events visit our Instagram
Page: http://instagram.com/nasdaq
For news tweets, please visit our Twitter page
at: http://twitter.com/nasdaq
For exciting viral content and ceremony photos visit Tumblr
Page: http://nasdaq.tumblr.com/
Webcast: A webcast of the Nasdaq Closing Bell
will be available at: https://new.livestream.com/nasdaq/live or
http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos: To obtain a hi-resolution photograph of
the Market Close, please go to
http://www.nasdaq.com/reference/marketsite_events.stm and click on
the market close of your choice.
About Nexvet Biopharma plc
(Nasdaq:NVET): Nexvet is a veterinary biologics developer
focused on transforming the therapeutic market for companion
animals, such as dogs and cats, by developing and commercializing
novel, species-specific biologics. Nexvet's proprietary PETization™
platform is designed to rapidly design monoclonal antibodies
("mAbs") that are recognized as "self" or "native" by an animal's
immune system, a property Nexvet refers to as "100%
species-specificity." Nexvet's product candidates also build upon
the safety and efficacy data from clinically tested human
therapies, thereby reducing clinical risk and development cost.
Nexvet is leveraging diverse global expertise and incentives to
build a vertically integrated biopharmaceutical company, which
conducts drug discovery in Australia, clinical development in the
United States and Europe and is growing its biomanufacturing
capabilities in Ireland.
About Nasdaq: Nasdaq (Nasdaq:NDAQ) is a
leading provider of trading, clearing, exchange technology,
listing, information and public company services across six
continents. Through its diverse portfolio of solutions, Nasdaq
enables customers to plan, optimize and execute their business
vision with confidence, using proven technologies that provide
transparency and insight for navigating today's global capital
markets. As the creator of the world's first electronic stock
market, its technology powers more than 70 marketplaces in 50
countries, and 1 in 10 of the world's securities transactions.
Nasdaq is home to more than 3,600 listed companies with a market
value of approximately $8.8 trillion and more than 10,000 corporate
clients. To learn more, visit: nasdaq.com/ambition or
business.nasdaq.com.
-NDAQA-
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From Sep 2023 to Sep 2024